Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Acellular Tissue Engineered Vessel

Phase 3

HHumacyte, Inc.

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

VascularNot yet recruiting

VascularPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Vascular

NCT07762313

Q3 2030

ApprovedNot yet recruiting

Vascular

NCT07762794

Clinical

Trials by Indication[1]

Vascular2 trials

A Prospective, Multi-center, Open-label Study, to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury When Autologous Vein Graft is Not Feasible.

Not yet recruiting·HHumacyte, Inc.·Phase 3·NCT07762313·10 enrolled

A Phase 4 Observational Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting for Arterial Replacement or Reconstruction in Patients With Extremity Vascular Trauma

Not yet recruiting·HHumacyte, Inc.·Approved·NCT07762794·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Acellular Tissue Engineered Vessel. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Acellular Tissue Engineered Vessel. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Humacyte, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: HHumacyte, Inc.

Related News